Currently, there are 2.55M common shares owned by the public and among those 2.55M shares have been available to trade.
The company’s stock has a 5-day price change of 35.23% and -34.97% over the past three months. BPTH shares are trading -87.15% year to date (YTD), with the 12-month market performance down to -83.92% lower. It has a 12-month low price of $0.85 and touched a high of $21.60 over the same period. BPTH has an average intraday trading volume of 333.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.75%, 3.60%, and -69.66% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Bio-Path Holdings Inc (NASDAQ: BPTH) shares accounts for 19.49% of the company’s 2.55M shares outstanding.
It has a market capitalization of $3.03M and a beta (3y monthly) value of 0.23. The earnings-per-share (ttm) stands at -$17.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.08% over the week and 9.01% over the month.
Earnings per share for the fiscal year are expected to increase by 81.56%, and 34.84% over the next financial year.
Looking at the support for the BPTH, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on March 11, 2021, with the firm’s price target at $13. H.C. Wainwright coverage for the Bio-Path Holdings Inc (BPTH) stock in a research note released on November 13, 2017 offered a Buy rating with a price target of $1.50. Maxim Group was of a view on August 10, 2016 that the stock is Buy, while Rodman & Renshaw gave the stock Buy rating on April 18, 2016, issuing a price target of $5. Maxim Group on their part issued Buy rating on June 02, 2014.
